YDES
YD Bio Limited Ordinary Shares
1W: +42.6%
1M: -8.3%
3M: -36.1%
YTD: -35.6%
$7.81
+0.08 (+1.03%)
After Hours: $7.87 (+0.06, +0.70%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$545.1M
52W Range5.3-25
Volume11,855
Avg Volume36,298
Beta0.17
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOEthan Shen
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2025-08-29
Websiteydesgroup.com
No. 3, Xingnan St.
Taipei 115001
TW
Taipei 115001
TW
About YD Bio Limited Ordinary Shares
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.
Latest News
12 Health Care Stocks Moving In Tuesday's Intraday Session
YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform
YD Bio (NASDAQ:YDES) Shares Down 9.9% – Here’s What Happened
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hen Man Edmund | 0 | — | 2026-03-18 |